- Isocorydine
-
- $47.00 / 5mg
-
2024-11-19
- CAS:475-67-2
- Min. Order:
- Purity: 98.19%
- Supply Ability: 10g
- Isocorydine
-
- $0.00 / 20mg
-
2023-02-24
- CAS:475-67-2
- Min. Order: 20mg
- Purity: ≥98%(HPLC)
- Supply Ability: 100 g
|
| | ISOCORYDINE HYDROCHLORIDE Basic information |
| | ISOCORYDINE HYDROCHLORIDE Chemical Properties |
| Melting point | 216-220 °C(lit.) | | alpha | D20 +195° (chloroform) | | Boiling point | 477.03°C (rough estimate) | | density | 1.2064 (rough estimate) | | refractive index | 1.5614 (estimate) | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | Cryst. | | pka | 9.41±0.20(Predicted) | | color | White to off-white |
| WGK Germany | 3 | | RTECS | CE1057950 | | Toxicity | LD50 intraperitoneal in mouse: 104mg/kg |
| | ISOCORYDINE HYDROCHLORIDE Usage And Synthesis |
| Description | Isocorydine is an aporphine alkaloid that has been found in A. squamosa that has vasodilatory and anticancer activities. It reduces the action potential duration and increases the effective refractory period in isolated canine Purkinje fibers when used at a concentration of 30 μM. Isocorydine induces relaxation of norepinephrine-precontracted isolated rabbit aortic strips with an EC50 value of 12.6 μM. It is cytotoxic to A549 lung cancer cells (IC50 = 197.7 μM), as well as Huh7, HepG2, SNU-449, and SNU-387 hepatic cancer cells (IC50s = 161.3, 148, 262.2, and 254.1 μg/ml, respectively). Isocorydine, in combination with doxorubicin, reduces tumor growth in a Huh7 mouse xenograft model. | | Uses | Isocorydine is an alkaloid inhibitor of eukaryotic kinases. | | Uses | sedative, cholinergic | | Uses | Isocorydine Hydrochloride is the hydrochloric acid of Isocorydine(I797000) which is an alkaloid inhibitor of eukaryotic kinases. | | Definition | ChEBI: Isocorydine is an aporphine alkaloid. | | in vivo | Isocorydine (intraperitoneal injection; 0.4 mg/kg; every 2 days for 2 weeks) retards the tumor growth, but the combined treatment of Doxorubicin (DOX) or ICD significantly inhibits tumor growth[1]. | Animal Model: | Female nude mice[1] | | Dosage: | 0.4 mg/ml | | Administration: | Injected intraperitoneally every 2 days for 2 weeks | | Result: | Combined treatment of isocorydine and DOX showed a promising potential to eradicate HCC. |
| | target | Dopamine Receptor | P450 (e.g. CYP17) | | References | See Isocorydine |
| | ISOCORYDINE HYDROCHLORIDE Preparation Products And Raw materials |
|